On the basis of a HER2 nanobody called SNA004, a site‐specific coupled radiotracer of 68Ga‐NODAGA‐SNA004‐GSC was developed to monitor the tumour response to trastuzumab and HER2‐targeting ADCs [182]. This evidence concerns the gene ERBB2 and neoplasm.